DekaBank Deutsche Girozentrale Cuts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

DekaBank Deutsche Girozentrale cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 113,042 shares of the biopharmaceutical company’s stock after selling 24,843 shares during the period. DekaBank Deutsche Girozentrale owned about 0.09% of Alnylam Pharmaceuticals worth $17,315,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Alnylam Pharmaceuticals by 8.1% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock valued at $4,964,000 after purchasing an additional 2,500 shares in the last quarter. Cetera Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the 1st quarter worth about $238,000. Burney Co. boosted its position in shares of Alnylam Pharmaceuticals by 371.9% during the 1st quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock worth $4,044,000 after acquiring an additional 21,325 shares in the last quarter. Swedbank AB purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $3,084,000. Finally, Plato Investment Management Ltd raised its position in shares of Alnylam Pharmaceuticals by 2,666.3% during the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 4,346 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares in the company, valued at $1,253,589.60. The disclosure for this sale can be found here. Insiders have sold 89,598 shares of company stock worth $19,377,944 over the last quarter. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY traded up $3.44 during trading hours on Friday, reaching $272.05. The company’s stock had a trading volume of 1,714,383 shares, compared to its average volume of 878,731. The company’s 50-day moving average is $208.99 and its two-hundred day moving average is $174.65. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $274.93. The stock has a market cap of $34.41 billion, a PE ratio of -101.51 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. During the same period in the previous year, the firm posted ($2.21) EPS. The company’s revenue for the quarter was up 107.0% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on ALNY shares. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a research note on Friday. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a “neutral” rating in a research note on Wednesday, July 3rd. SVB Leerink lifted their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday, June 25th. Finally, Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the company a “buy” rating in a research report on Friday. Eight analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $269.32.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.